Michael Ulz
Stock Analyst at Morgan Stanley
(3.72)
# 659
Out of 4,765 analysts
118
Total ratings
46.67%
Success rate
8.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $10.54 | +175.14% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $4.89 | +43.15% | 7 | Mar 5, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $49 → $45 | $4.20 | +971.43% | 11 | Mar 5, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $75 → $54 | $7.50 | +620.00% | 5 | Mar 3, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $3.82 | +423.56% | 4 | Feb 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $275 → $284 | $240.79 | +17.95% | 9 | Feb 14, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Equal-Weight | $20 → $5 | $3.50 | +42.86% | 5 | Feb 12, 2025 | |
| GUTS Fractyl Health | Maintains: Overweight | $18 → $10 | $1.37 | +629.93% | 2 | Feb 3, 2025 | |
| AKRO Akero Therapeutics | Maintains: Overweight | $46 → $96 | $45.23 | +112.25% | 4 | Jan 28, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Overweight | $105 | $29.35 | +257.75% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $12.21 | +325.88% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $115 | $89.90 | +27.92% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $45.52 | +25.23% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $15.68 | +72.19% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $2.54 | +1,474.80% | 1 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $0.99 | +607.07% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $23 → $12 | $9.50 | +21.05% | 4 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $25 | $1.91 | +1,208.90% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $33.13 | +44.88% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $8.00 | +237.50% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $3.32 | +502.41% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.76 | +413.70% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.82 | +1,119.51% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $0.25 | +3,165.31% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $1.75 | +71.43% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $7.22 | +315.51% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.35 | +2,122.22% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $7.50 | +500.00% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.51 | +3,833.14% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $40.42 | +97.92% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $8.92 | +68.16% | 3 | Jul 12, 2017 |
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $10.54
Upside: +175.14%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $4.89
Upside: +43.15%
Silence Therapeutics
Mar 5, 2025
Maintains: Overweight
Price Target: $49 → $45
Current: $4.20
Upside: +971.43%
Karyopharm Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $75 → $54
Current: $7.50
Upside: +620.00%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.82
Upside: +423.56%
Alnylam Pharmaceuticals
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $275 → $284
Current: $240.79
Upside: +17.95%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20 → $5
Current: $3.50
Upside: +42.86%
Fractyl Health
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.37
Upside: +629.93%
Akero Therapeutics
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $45.23
Upside: +112.25%
Viking Therapeutics
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $29.35
Upside: +257.75%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $12.21
Upside: +325.88%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $89.90
Upside: +27.92%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $45.52
Upside: +25.23%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $15.68
Upside: +72.19%
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $2.54
Upside: +1,474.80%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $0.99
Upside: +607.07%
Jan 5, 2024
Downgrades: Underweight
Price Target: $23 → $12
Current: $9.50
Upside: +21.05%
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $1.91
Upside: +1,208.90%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $33.13
Upside: +44.88%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $8.00
Upside: +237.50%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $3.32
Upside: +502.41%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $8.76
Upside: +413.70%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.82
Upside: +1,119.51%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.25
Upside: +3,165.31%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $1.75
Upside: +71.43%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $7.22
Upside: +315.51%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.35
Upside: +2,122.22%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $7.50
Upside: +500.00%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.51
Upside: +3,833.14%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $40.42
Upside: +97.92%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $8.92
Upside: +68.16%